**Abstract**

Several previous case reports have shown that clozapine treatment occasionally induces elevation of creatine phosphokinase (CPK) levels. We describe a patient with marked elevations of CPK following initiation of clozapine treatment.

The case was a 41-year-old woman who was first diagnosed with schizophrenia at the age of 25 due to auditory hallucination and delusions of persecution. She was admitted to our psychiatric ward at the age of 41 due to aggressive behaviors and worsening of psychotic symptoms. Treatment with antipsychotics including quetiapine, olanzapine, and aripiprazole as well as with electroconvulsive therapy was ineffective in relieving her symptoms. Clozapine was begun on day 162 of admission at the dose of 12.5 mg/day and was gradually increased to 600 mg/day by day 232. On day 286, she had a generalized tonic-clonic seizure. Because she had no past history of epilepsy, we suspected clozapine to be the cause of the seizure. Therefore, the dose was decreased to 400 mg/day the following day. Her serum levels of CPK were 1079 U/L, 6454 lU/L, and 7509U/L on days 287, 290, and 291, respectively. Clozapine was discontinued on day 291. Serum CPK level decreased to 5224 U/L on day 293. An isoenzyme study showed that the CPK was almost exclusively of skeletal muscle origin. Malignant syndrome was unlikely due to the lack of fever, rigidity, and increased white blood cell count. Because clozapine was the only effective treatment for her psychotic symptoms, clozapine was restarted on day 297. After 56 days of treatment with clozapine 400mg/day, no relapse of seizures or CPK elevation has been observed.

An elevated CPK level is one of the adverse events observed in those prescribed clozapine. However, readministration of clozapine with close monitoring after the occurrence of such adverse effect may be a treatment option.
